Bioavailability and systemic transport of oleanolic acid in humans, formulated as a functional olive oil.

Evidence of the pharmacological activity of oleanolic acid (OA) suggests its potential therapeutic application. However, its use in functional foods, dietary supplements, or nutraceuticals is hindered by limited human bioavailability studies. The BIO-OLTRAD trial is a double-blind, randomized controlled study with 22 participants that received a single dose of 30 mg OA formulated as a functional olive oil. The study revealed that the maximum serum concentration of OA ranged from 500 to 600 ng mL-1, with an AUC0-∞ value of 2862.50 ± 174.50 ng h mL-1. Furthermore, we discovered a physiological association of OA with serum albumin and triglyceride-rich lipoproteins (TRL). UV absorption spectra showed conformational changes in serum albumin due to the formation of an adduct with OA. Additionally, we demonstrated that TRL incorporate OA, reaching a maximum concentration of 140 ng mL-1 after 2-4 hours. We conjecture that both are efficient carriers to reach target tissues and to yield high bioavailability.

Telemedicine screening program for diabetic retinopathy in patients with type 1 diabetes mellitus.

PURPOSE: To analyze the results of the telemedicine screening program for diabetic retinopathy (DR) in patients with type 1 diabetes conducted by the Endocrinology and Nutrition Management Unit of Virgen del Rocío University Hospital. METHODS: This cross-sectional study comprised patients with type 1 diabetes mellitus (DM) in our DR screening program from January 2018 to November 2020. Fundus photographs are performed by trained nurses and reviewed by a trained endocrinologist. Those suggestive of pathology are sent to ophthalmology through a telematic program for review. RESULTS: Of the 995 fundus photographs evaluated, 646 (65.3%) showed no evidence of DR, 327 (33.1%) presented possible DR, and 16 (1.6%) were not gradable. The diagnosis was confirmed in 254 patients after reviewing by ophthalmology, and the screening program achieved a positive predictive value for DR of 77.7%. Seventy-three were excluded by ophthalmology due to the absence of DR (false positive rate - 22.3%). In 92.5% of the cases classified by the ophthalmologist, the degree of DR was mild or very mild. CONCLUSION: Our telemedicine screening program for DR in patients with type 1 DM is consistent with the literature. Effective screening for DR is performed, with patients diagnosed in the early stages. Telemedicine programs facilitate efficient communication among healthcare personnel.

Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring.

This study aimed to evaluate the effectiveness and safety of the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system in people with type 1 diabetes (T1D) previously treated with continuous subcutaneous insulin infusion combined with flash glucose monitoring in a real-life setting. A total of 47 subjects (mean age 41 ± 13.6 years, 60% females, diabetes duration 28 ± 11 years) were included and switched to an AHCL system. Baseline and 6-month data were analyzed. Time in range 70-180 mg/dL increased from 65.3% at baseline to 73.8% at 6 months. Time in hyperglycemia >180 mg/dL decreased from 26.6% to 19.3%. Time in hypoglycemia <70 mg/dL decreased from 4.6% to 2.3%. The coefficient of variation also decreased from 36% to 31.6%. No episodes of severe hypoglycemia, diabetes ketoacidosis, or diabetes-related hospital admissions occurred. In conclusion, the MiniMed 780G AHCL system enables the safe achievement of recommended glycemic targets in people with T1D after 6 months of use.

[Treatment applied to post-perfusion phlebitis]. / Tratamientos aplicados a las flebitis posperfusión.

During the physio-pathological process which causes phlebitis, a vesicular constriction and an aggregation of platelets occurs. Therefore, the authors believe that the application of a vesicular dilator such as nitroglycerine would alleviate the symptoms of post-perfusion phlebitis and would be an alternate treatment to the commonly utilized heparinized cream, about whose effectiveness in treating this medical problem virtually no documentation exists.

Tratamientos aplicados a las flebitis posperfusión / Treatment applied to post-perfusssion phlebitis

Durante el proceso fisiopatológico que produce la flebitis, tiene lugar una vasoconstricción y una agregación plaquetaria. Por tanto, pensamos que la aplicación de un vasodilatador como ...lan itroglicerina, mejorarra los síntomas,de la flebitis posperfusión y serIa un tratamiento alternativo a la comúnmente utilizada pomada de heparinoides, sobre cuya eficacia en el tratamiento de esta dolencia no existe ~~penas documentación., Analizamos 22 pacientes ingresados en la Unidad de Medicina Interna de un hospital de nuestra ciudad, que padecían flebitis secundaria a infusión endovenosa, a los cuales se les aplicó, de forma aleatoria, uno de los dos tratamientos en estudio: parches trans-, dérmicos de nitroglicerina de 5 mg versus pomada de heparinoides. Fueron 11 pacientes en cada grupo. Concluimos que la flebitisposperfusión es un problema bastante común en pacientes hospitalizados, y sus síntomas pueden ser eficazmente reducidos con el uso de parches de nitroglicerina como tratamiento

During the physio-pathological process which causes phlebitis, a vesicular constriction and an aggregation of platelets occurs. Therefore, the authors believe that the application of a vesicular dilatar such as nitroglycerine would alleviate the symptoms of post-perfusion phlebitis and would be an alternate treatment to the commonly utilized heparinized crea m, about whose effectiveness in treating this medical problem virtually no documentation exists. The authors analyzed 22 patients checked into the Infernal Medicine Unit in a hospital in their city who were suffering from phlebitis as a secondary effect to an endovenous infusion to whom randomly had been applied one of the two treatments used in this study: a trans-dermal patch having 5 mg of nitroglycerine versus a heparinized cream. There were eleven patients in each study group. The authors conclude that post-perfusion phlebitis is a quite common problem in hospitalized patients and their symptoms can be effectively reduced by the use of nitroglycerine patches as treatment